Our first step was to determine whether the PNPLA3 GG variant LAMPS and wild-type CC LAMPS in the EMS “lifestyle” state would respond distinctly to the recently approved drug, resmetirom, a liver-targeted THR-β-selective agonist designed to target causes of MASH with moderate-to-advanced liver fibrosis (Harrison et al., 2024; Harrison et al., 2019; Harrison et al., 2023). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.